Cortexa Bolsters Leadership in Australian MDMA Supply for FY2026

Key Facts

1Cortexa is a 50/50 joint venture between PharmAla Biotech and Vitura Health.

2The company reaffirms its market-leading position for MDMA supply for FY2026 in Australia.

3The joint venture focuses on providing psychedelic medicines to the Australian market.

Cortexa, a 50/50 joint venture between PharmAla Biotech and Vitura Health, has announced significant progress in the commercialization of MDMA supply within Australia. The company reaffirmed its position as a market leader for the 2026 fiscal year, solidifying its presence in the emerging psychedelic medicine sector. This development follows strategic regulatory shifts in Australia that now permit the use of psychedelic-assisted therapies for specific medical conditions. Cortexa aims to establish a dominant and reliable supply chain to meet the rising demand for clinical applications across the country. The partnership effectively leverages PharmAla’s manufacturing expertise alongside Vitura Health’s robust distribution network. Investors view this as a positive milestone for the parent companies, CSE: MDMA and ASX: VIT, as it secures long-term revenue potential in a specialized pharmaceutical niche.